The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Tirzepatide as Compared with Semaglutide for the Treatment of …
May 11, 2025 · In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum …
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with …
Mar 1, 2025 · Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor. 21,22 Tezepelumab administered subcutaneously …
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care.
Lepodisiran - The New England Journal of Medicine
Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …
Zongertinib in Previously Treated - The New England Journal of …
Apr 28, 2025 · In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to …
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple …
Apr 8, 2025 · Tolebrutinib is an oral, brain-penetrant, and bioactive BTK inhibitor intended to target disease-associated microglia and B cells within the CNS in addition to their counterparts …
VITT-like Monoclonal Gammopathy of Thrombotic Significance
Feb 12, 2025 · Anti‐ PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT ‐like and VITT ‐like characteristics , British Journal …
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase …
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
Apr 23, 2025 · Uncontrolled hypertension remains a leading cause of cardiovascular complications and death from cardiovascular disease. 1 Despite the use of multidrug …